Quick Search 
Drugs of the Future
Register or sign in

Instructions for Authors 
Subscription Information


Drugs of the Future is an interdisciplinary biomedical research journal that publishes well-documented, peer-reviewed articles on topics emerging from the confluence of scientific fields including chemistry, biology, pharmacology, genomics and medicine. The journal identifies and anticipates new trends, advances and breakthroughs in basic, translational and clinical research, and includes the following sections:

Monographs, containing comprehensive product information on new compounds in development, including synthesis, preclinical pharmacology, pharmacokinetics and metabolism, safety, clinical studies and drug interactions.

Review articles, highlighting therapeutic approaches for the treatment of diseases, compounds under development and those in clinical use.

Filling the Gaps in Drug Therapy, covering therapeutic progress in diseases and conditions, some rare and others all too common, for which no effective therapy currently exists, or for which existing therapies are poorly tolerated or otherwise unsatisfactory.

Targets to Watch, highlighting targets with potential in drug development.

Biomarkers to Watch, focusing on biomarkers undergoing early clinical evaluation for their use in diagnosis, treatment efficacy and target identification.

Pipeline on the Move, presented in tabular format, reporting on recent changes or milestones detected on the status of drugs currently under active development.

NME Digest, highlighting new, biologically active molecules revealed for the first time in current literature, at congresses and in company communications that are identified by a code number or the chemical name. They include compounds chosen for further pharmacological evaluation or as clinical candidates, new leads whose structural optimization could provide structural diversity of known mechanistic classes of drugs, and new pharmacological tools for investigating drug targets.

Congress/meeting reports, providing highlights from major scientific meetings around the world.

Indices, including a yearly pharmacostructural index, a cumulative formula index and a cumulative general index of names from 1976 to the present.


The Editorial Board comprises major authorities in their field who are selected to ensure that a wide variety of therapeutic areas are covered. The Board members recommend reviews from authorities within their filed to guarantee that all topics are covered comprehensively and that all issues of current importance are emphasized. Submitted articles are peer reviewed before publication.

Supplementary issues devoted to recently marketed drugs and symposia proceedings are periodically published. Supplements are written by leading specialists on the basis of current scientific literature and their own experience.

  • p-ISSN: 0377-8282, e-ISSN: 2013-0368 (B-47251-2009)

  • Established: 1976

  • Published: 12 issues/year plus annual index

  • Reader profile: Medicinal chemists, pharmacologists, molecular biologists and other researchers involved in the design, discovery and development of drugs/biologicals, target identification and validation, and the preclinical and clinical development of treatments for both common and rare and neglected diseases and conditions, and corporate strategy directors

  • Indexed in: PubChem®, Current Contents®-Life Sciences, Biological Abstracts®, Chemical Abstracts®, EMBASE, ISI® SciSearch®, BIOSIS Previews®, Science Citation Index Expanded™, Web of Science®, Current Contents Connect®, Journal Citation Reports®, PubMed Central®

Editorial Team

Editor in Chief: David Andreu, Pompeu Fabra University, Barcelona, Spain

Managing Editor: M.K. Tracy

Assistant Editors: P. Avello, X. Bofill, J. Bolòs, V. Carceller, P. Cole, C. Dulsat, D. Fernández-Forner, A.I. Graul, E. Rosa, L. Sorbera, E. Torremadé, C. Vergés, M. Viadiu

Editorial Coordinator: C. Todd

Scientific Advisory Board

M. Abou-Gharbia (Temple University, USA)
M.J. Aminoff (University of California, San Francisco, USA)
J.K. Amory (University of Washington, USA)
S. Antoniu (Grigore T. Popa University of Medicine and Pharmacy, Romania)
F.C. Barone (SUNY Downstate Medical Center, USA)
H. Boshoff (LCIA, NIAID, NIH, USA)
D. Brooks (Janssen Pharmaceutical Companies of Johnson & Johnson, USA)
P.P. Claudio (University of Mississippi, USA)
L. de Angelis (University of Trieste, Italy)
E. de Clercq (Katholieke Universität Leuven, Belgium)
H.J. Federsel (AstraZeneca, Sweden)
P.B. Fernandes (Cempra, Inc., USA)
F.W. Fraunfelder (Casey Eye Institute, USA)
M. Hall (NCI, NIH, USA)
D. Howat (HBS Consulting, France)
K. Jarnagin (Anacor Pharmaceuticals, USA)
G.M. Keserü (Hungarian Academy of Sciences, Hungary)
S.K. Kulkarni (Panjab University, India)
B. Leonard (National University of Ireland, Ireland)
P.L. Lorenzi (M.D. Anderson Cancer Center, USA)
R. McArthur (McArthur and Associates GmbH, Switzerland)
J. Mixson (University of Maryland, USA)
H. Mucke (HM Pharma Consultancy, Austria)
D. Newman (NCI, USA)
K. Onodera (Spica Research, Japan)
R. Panchagnula (Pfizer Pharmaceutical, India)
J.T. Pento (University of Oklahoma Health Sciences Center, USA)
M. Pineda (Hospital Sant Joan de Deu, Spain)
S. Rádl (ZeNTIVA, a Sanofi company, Czech Rep.)
G. Romano (Temple University, USA)
J.K. Shen (Shanghai Institute of Materia Medica, China)
Z. Temesgen (Mayo Clinic, USA)
J.R. Wu-Wong (University of Illinois at Chicago/Vidasym, USA)
W.C. Zamboni (University of North Carolina, USA)

© 2021 Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy